RAS and BRAF in metastatic colorectal cancer management

The treatment of metastatic colorectal cancer (mCRC) has been further refined with the development of monoclonal antibodies, cetuximab and panitumumab, towards the epidermal growth factor receptor (EGFR). Anti-EGFR therapy has afforded improved survival in those with wild-type RAS mCRC but provides...

Full description

Saved in:
Bibliographic Details
Published in:J Gastrointest Oncol
Main Authors: Gong, Jun, Cho, May, Fakih, Marwan
Format: Artigo
Language:Inglês
Published: AME Publishing Company 2016
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5056249/
https://ncbi.nlm.nih.gov/pubmed/27747083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.06.12
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items